[Secondary amyloidosis associated with rheumatoid arthritis (RA)].
Koseki
Yumi
Y
Division of Rheumatic Disease, Tokyo Metropolitan Ohtsuka Hospital.
Goto
Makoto
M
D000686:Amyloidosis / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications*; D018753:Diet, Protein-Restricted; D000068800:Etanercept; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D010951:Plasma Exchange; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D006435:Renal Dialysis; D000685:Serum Amyloid A Protein / Q000235:genetics / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000685:Serum Amyloid A Protein; D011239:Prednisolone; D000069285:Infliximab; D000068800:Etanercept